To explore the feasibility of targeting HN1L/PLK1 signaling in the treatment of ESCC, PLK1 inhibitor BI-2536 was used to treat KYSE30 cells with or without HN1L overexpression in vitro and in vivo. This evidence concerns the gene PLK1 and esophageal squamous cell carcinoma.